Synlogic (NASDAQ:SYBX) Rating Lowered to Sell at HC Wainwright

Synlogic (NASDAQ:SYBXGet Free Report) was downgraded by stock analysts at HC Wainwright from a “buy” rating to a “sell” rating in a report issued on Friday, MarketBeat Ratings reports. HC Wainwright also issued estimates for Synlogic’s FY2028 earnings at $7.05 EPS.

Several other analysts also recently weighed in on SYBX. Alliance Global Partners began coverage on shares of Synlogic in a research report on Monday, December 11th. They set a “buy” rating and a $30.00 price objective for the company. SVB Leerink reissued a “market perform” rating on shares of Synlogic in a research report on Friday. Finally, Chardan Capital lowered Synlogic from a “buy” rating to a “neutral” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Synlogic presently has a consensus rating of “Hold” and a consensus target price of $65.00.

View Our Latest Analysis on SYBX

Synlogic Price Performance

Shares of NASDAQ SYBX opened at $1.77 on Friday. The business has a 50-day moving average of $3.47 and a two-hundred day moving average of $4.18. The company has a market capitalization of $16.27 million, a price-to-earnings ratio of -0.14 and a beta of 1.21. Synlogic has a 1 year low of $1.60 and a 1 year high of $13.95.

Synlogic (NASDAQ:SYBXGet Free Report) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($2.57) earnings per share for the quarter, missing the consensus estimate of ($2.55) by ($0.02). The business had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $0.04 million. Synlogic had a negative return on equity of 95.30% and a negative net margin of 8,396.04%. As a group, equities research analysts expect that Synlogic will post -6.25 earnings per share for the current year.

Hedge Funds Weigh In On Synlogic

Hedge funds have recently modified their holdings of the business. Northern Trust Corp raised its position in Synlogic by 21.6% in the 1st quarter. Northern Trust Corp now owns 93,863 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 16,704 shares during the last quarter. UBS Group AG acquired a new position in Synlogic in the first quarter valued at $84,000. State Street Corp raised its holdings in shares of Synlogic by 48.1% in the first quarter. State Street Corp now owns 127,765 shares of the biotechnology company’s stock valued at $307,000 after buying an additional 41,509 shares during the last quarter. Ensign Peak Advisors Inc acquired a new stake in shares of Synlogic during the first quarter worth about $79,000. Finally, Alyeska Investment Group L.P. grew its holdings in shares of Synlogic by 2.9% during the first quarter. Alyeska Investment Group L.P. now owns 2,590,945 shares of the biotechnology company’s stock worth $6,218,000 after buying an additional 74,239 shares during the last quarter. 47.18% of the stock is currently owned by hedge funds and other institutional investors.

Synlogic Company Profile

(Get Free Report)

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.

Featured Stories

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.